Virtual Biopsy Market Report 2026

Virtual Biopsy Market Overview

• Virtual Biopsy market size has reached to $0.71 billion in 2025 • Expected to grow to $1.23 billion in 2030 at a compound annual growth rate (CAGR) of 11.7% • Growth Driver: Rising Prevalence Of Oncological Disorders Fueling The Growth Of The Market Due To Increasing Cancer Cases And Non-Invasive Diagnosis Methods • Market Trend: AI-Driven Platform Enhances Non-Invasive Disease Detection With Advanced MRI Technology • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Virtual Biopsy Market?

Virtual biopsy is a non-invasive diagnostic technique that uses advanced imaging technologies combined with computer algorithms to analyze tissues for signs of disease. Its primary purpose is to detect abnormalities, such as tumors or infections, without the need for a traditional tissue sample, reducing risks and recovery time for patients. This method is safer, faster, and less painful than traditional biopsies. The main target therapeutic areas of virtual biopsy include oncological disorders, neurological disorders, cardiovascular disorders, ophthalmological disorders, endocrine disorders, gastrointestinal disorders, and other related conditions. Oncological disorders encompass a group of diseases marked by the uncontrolled growth and spread of abnormal cells, commonly known as cancer, which can affect various organs and tissues. Virtual biopsy targets various cancers, such as solid malignancies, breast cancer, lung cancer, prostate cancer, colorectal cancer, brain cancer, and others. The imaging technologies used in virtual biopsy include magnetic resonance imaging (MRI), computed tomography (CT), X-ray, ultrasound, and others, and are used for end users, including hospitals and clinics, research institutes, diagnostic centers, and others.

What Is The Virtual Biopsy Market Growth Forecast?

The virtual biopsy market size is expected to see rapid growth in the next few years. It will grow to $1.23 billion in 2030 at a compound annual growth rate (CAGR) of 11.7%. The growth in the forecast period can be attributed to advancements in imaging algorithms and ai analytics, expansion of oncology and neurological diagnostic applications, increasing adoption in cardiovascular and ophthalmological disorders, integration with personalized medicine approaches, rising investment in research institutes and diagnostic centers. Major trends in the forecast period include increased adoption of non-invasive diagnostic procedures, rising demand for early disease detection, integration of advanced imaging with predictive analytics, expansion of virtual biopsy applications across multiple therapeutic areas, growing focus on patient comfort and reduced recovery time.

Global Virtual Biopsy Market Segmentation

1) By Target Thrapeutic Areas: Oncological Disorders, Neurological Disorders, Cardiovascular Disorders, Ophthalmological Disorders, Endocrine Disorders, Gastrointestinal Disorders, Other Target Therapeutic Areas 2) By Cancer Targeted: Solid Malignancies, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Cancer, Other Cancer Targeteds 3) By Imaging Technologies: Magnetic Resonance Imaging, Computed Tomography, X-Ray, Ultrasound, Other Imaging Technologies 4) By End Users: Hospitals And Clinics, Research Institutes And Diagnostic Centers, Other End Users Subsegments: 1) By Oncological Disorders: Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Liver Cancer, Brain Tumors, Other Cancers 2) By Neurological Disorders: Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Epilepsy, Brain Injuries, Stroke, Other Neurological Conditions 3) By Cardiovascular Disorders: Coronary Artery Disease, Heart Failure, Arrhythmias, Aortic Aneurysm, Valvular Heart Disease, Myocardial Infarction, Other Cardiovascular Conditions 4) By Ophthalmological Disorders: Age-Related Macular Degeneration, Diabetic Retinopathy, Glaucoma, Retinal Vein Occlusion, Cataracts, Other Eye Disorders 5) By Endocrine Disorders: Diabetes Mellitus, Thyroid Disorders, Adrenal Gland Disorders, Pituitary Gland Disorders, Parathyroid Disorders, Other Endocrine Conditions 6) By Gastrointestinal Disorders: Inflammatory Bowel Disease, Colorectal Polyps, Gastric Ulcers, Liver Cirrhosis, Pancreatic Disorders, Hepatitis, Other Gastrointestinal Conditions 7) By Other Target Therapeutic Areas: Musculoskeletal Disorders, Renal Disorders, Pulmonary Disorders, Hematologic Disorders, Dermatological Disorders, Infectious Diseases, Other Miscellaneous Conditions

What Are The Drivers Of The Virtual Biopsy Market?

The rising prevalence of oncological disorders is expected to propel the growth of the virtual biopsy market going forward. Oncological disorders are health conditions related to cancer, where abnormal cells grow and spread in the body. The rising prevalence of oncological disorders is primarily due to lifestyle changes such as poor diet, physical inactivity, tobacco use, and increasing exposure to environmental pollutants. Virtual biopsy enhances the diagnosis and monitoring of oncological disorders by providing noninvasive, real-time imaging insights that reduce the need for traditional tissue biopsies while improving accuracy and patient safety. For instance, in January 2023, according to the Rock Health, a U.S.-based digital health research firm, reported that 1,958,310 new cancer cases are projected in the U.S. for 2023, up from about 1.9 million new cases in 2022. Therefore, the rising prevalence of oncological disorders is driving the growth of the virtual biopsy industry. The increased demand for telemedicine is expected to propel the growth of the virtual biopsy market going forward. Telemedicine refers to the remote delivery of healthcare services using digital communication technologies, such as video conferencing, mobile apps, and telecommunication networks. The increased demand for telemedicine is due to improved healthcare access, cost efficiency, and advancements in digital health technologies. Virtual biopsy supports telemedicine by enabling remote, non-invasive tissue assessment through advanced imaging and AI-powered analysis, allowing clinicians to monitor and diagnose patients without requiring in-person visits, which enhances accessibility and continuity of care. For instance, in July 2023, according to Harmony Healthcare IT, a US-based data management firm, 62% of Americans had used telehealth services for their medical needs, and more than three-quarters (77%) saw it as the future of healthcare. Therefore, the increased demand for telemedicine is driving the growth of the virtual biopsy industry.

Key Players In The Global Virtual Biopsy Market

Major companies operating in the virtual biopsy market are Siemens Healthineers AG, GE Healthcare, Canon Medical Systems, Philips Healthcare, Fujifilm Healthcare, Esaote SpA, Samsung Medison, Perspectum Ltd, QUIBIM SL, ImageBiopsy Lab GmbH, Deep Bio Inc, BrainSpec Inc, Oncoustics Inc, AI Metrics LLC, Zebra Medical Vision, Arterys Inc, Aidoc Medical, Viz ai, Subtle Medical, Gleamer AI

Global Virtual Biopsy Market Trends and Insights

Major companies operating in the virtual biopsy market are focusing on developing technologically advanced solutions and getting approvals, such as the magnetic resonance spectroscopy (MRS) platform, to enhance non-invasive diagnostic accuracy and provide real-time analysis for early disease detection and personalized treatment. Magnetic resonance spectroscopy (MRS) is a non-invasive imaging technique that helps virtual biopsy by providing detailed molecular information of tissues, enabling accurate, real-time disease detection and monitoring without the need for invasive procedures. For instance, in November 2023, BrainSpec Inc., a US-based healthtech company, received approval from the U.S. Food and Drug Administration (FDA) for the artificial intelligence (AI)-driven BrainSpec platform. This technology uses advanced artificial intelligence (AI) analysis of MR spectroscopy data to measure brain metabolites such as 2-hydroxyglutarate, facilitating non-invasive virtual biopsies for the diagnosis of conditions such as gliomas, alzheimer’s, and multiple sclerosis. The system integrates seamlessly with standard magnetic resonance imaging (MRI) scanners, automates data processing, and provides results within minutes. It also utilizes a reference database of brain chemistry to improve diagnostic accuracy.

Regional Outlook

North America was the largest region in the virtual biopsy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Virtual Biopsy Market?

The virtual biopsy market consists of revenues earned by entities by providing services such as imaging diagnostics, artificial intelligence (AI)-based interpretation, biomarker testing, telemedicine services, and three-dimensional (3D) tissue modeling. The market value includes the value of related goods sold by the service provider or included within the service offering. The virtual biopsy market also includes sales of biopsy needle systems, artificial intelligence (AI)-based diagnostic tools, endoscopic systems, and photoacoustic imaging devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.